Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

910 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
Speranza G, Anderson L, Chen AP, Do K, Eugeni M, Weil M, Rubinstein L, Majerova E, Collins J, Horneffer Y, Juwara L, Zlott J, Bishop R, Conley BA, Streicher H, Tomaszewski J, Doroshow JH, Kummar S. Speranza G, et al. Among authors: bishop r. Invest New Drugs. 2018 Apr;36(2):230-239. doi: 10.1007/s10637-017-0495-3. Epub 2017 Aug 12. Invest New Drugs. 2018. PMID: 28808818 Free PMC article. Clinical Trial.
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.
Do K, Speranza G, Chang LC, Polley EC, Bishop R, Zhu W, Trepel JB, Lee S, Lee MJ, Kinders RJ, Phillips L, Collins J, Lyons J, Jeong W, Antony R, Chen AP, Neckers L, Doroshow JH, Kummar S. Do K, et al. Among authors: bishop r. Invest New Drugs. 2015 Aug;33(4):921-30. doi: 10.1007/s10637-015-0255-1. Epub 2015 Jun 18. Invest New Drugs. 2015. PMID: 26082332 Free PMC article. Clinical Trial.
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.
Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, Streicher H, Mackall CL. Merchant MS, et al. Among authors: bishop r. Clin Cancer Res. 2016 Mar 15;22(6):1364-70. doi: 10.1158/1078-0432.CCR-15-0491. Epub 2015 Nov 3. Clin Cancer Res. 2016. PMID: 26534966 Free PMC article. Clinical Trial.
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors.
Takebe N, Coyne GO, Kummar S, Collins J, Reid JM, Piekarz R, Moore N, Juwara L, Johnson BC, Bishop R, Lin FI, Mena E, Choyke PL, Lindenberg ML, Rubinstein LV, Bonilla CM, Goetz MP, Ames MM, McGovern RM, Streicher H, Covey JM, Doroshow JH, Chen AP. Takebe N, et al. Among authors: bishop r. Oncotarget. 2021 Feb 16;12(4):268-277. doi: 10.18632/oncotarget.27887. eCollection 2021 Feb 16. Oncotarget. 2021. PMID: 33659039 Free PMC article.
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. Koh C, et al. Among authors: bishop r. Lancet Infect Dis. 2015 Oct;15(10):1167-1174. doi: 10.1016/S1473-3099(15)00074-2. Epub 2015 Jul 16. Lancet Infect Dis. 2015. PMID: 26189433 Free PMC article. Clinical Trial.
HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
Osinusi A, Rasimas JJ, Bishop R, Proschan M, McLaughlin M, Murphy A, Cortez KJ, Polis MA, Masur H, Rosenstein D, Kottilil S. Osinusi A, et al. Among authors: bishop r. J Acquir Immune Defic Syndr. 2010 Mar;53(3):357-63. doi: 10.1097/QAI.0b013e3181c7a29d. J Acquir Immune Defic Syndr. 2010. PMID: 20101190 Free PMC article. Clinical Trial.
A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.
Sibley CH, Chioato A, Felix S, Colin L, Chakraborty A, Plass N, Rodriguez-Smith J, Brewer C, King K, Zalewski C, Kim HJ, Bishop R, Abrams K, Stone D, Chapelle D, Kost B, Snyder C, Butman JA, Wesley R, Goldbach-Mansky R. Sibley CH, et al. Among authors: bishop r. Ann Rheum Dis. 2015 Sep;74(9):1714-9. doi: 10.1136/annrheumdis-2013-204877. Epub 2014 Jun 6. Ann Rheum Dis. 2015. PMID: 24906637 Free PMC article. Clinical Trial.
Selumetinib in Plexiform Neurofibromas.
Gross A, Bishop R, Widemann BC. Gross A, et al. Among authors: bishop r. N Engl J Med. 2017 Mar 23;376(12):1195. doi: 10.1056/NEJMc1701029. N Engl J Med. 2017. PMID: 28328340 No abstract available.
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA. Johnson LA, et al. Among authors: bishop rj. Blood. 2009 Jul 16;114(3):535-46. doi: 10.1182/blood-2009-03-211714. Epub 2009 May 18. Blood. 2009. PMID: 19451549 Free PMC article. Clinical Trial.
910 results